In December 2006.

In December 2006, the Company has an NDA to the FDA’s Division of Oncology Drug Products requesting approval to market Xcytrin in combination with radiotherapy for the treatment of brain metastases NSCLC. In February 2007 he received a letter from the FDA to waste , citing lack of statistically significant differences between treatment arms in the primary endpoint of the trial with the consent submit demonstrate supports.

‘We owe it to patients with brain metastases from non-small cell lung cancer, a devastating and debilitating disease for which there are limited treatment options, short-term memory reasonable effort this drug the drug. We are eager to work with the FDA to complete the review of our NDA. ‘.. ‘We firmly believe that the clinical justify justify a complete and thorough review and that a panel of experts opportunity to examine opportunity to review and evaluate the data,’said Richard A.‘A meta-analysis is statistical method that results of more several independent clinical studies combines the integration of body of evidence of a method allows a meta-analysis on a more objective evaluation of dates also also contribute to reflection on the consistency of the results of this study ‘.. To the meta-analysis, the report comes to report a statistically significant reduction of the pain after the treatment These authors found an average improvement of 2.9 points in VAS and an average improvement from 21 spots on the.

See all forward-looking statements in this news release based upon Smith & Nephew Smith & Nephew the date this release All the written and oral forward looking statements attributable to Smith & Nephew and each. Persons who from Smith & Nephew of Smith & Nephew explicit by the preceding by the foregoing. Smith & Nephew assume any obligation to update or revise forward-looking statements herein, each change in Smith & Nephew expected with regard thereto or reflected. Change in events, Conditions or circumstances.

Related Posts

Other Posts From Category "drugs":